Title : APG990, a monoclonal antibody targeting OX40L, demonstrates safety and an extended half-life in healthy subjects (P3237) Presenter : Carl Dambkowski, M.D., Chief Medical Officer, Apogee ...

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, will present initial data at their 10 ...

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Hengrui Pharma, a global ...

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, today announced the presentation of early efficacy and ...

Punekar, M.D., assistant professor of medicine, NYU Langone, Perlmutter Cancer Center, will share data from the EVEREST-2 study (poster number P3.18.87) during the Clinical Trials in Progress session ...

If you were a Facebook user at some point in the past 15 years, you may be receiving a payment from the popular social media ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced the presentation of new findings on its ...

Shares of Figure Technology Solutions Inc. jumped 21% in today’s trading session, bringing the newly listed blockchain ...

Treace Medical Concepts, Inc. ('Treace” or the 'Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot ...

The US Food and Drug Administration (FDA) will hold an advisory panel meeting in November to examine the fast-emerging class ...